Product Description: Y-27632 is an orally active, ATP-competitive inhibitor of ROCK-I and ROCK-II, with Kis of 220 and 300 nM, respectively. Y-27632 attenuates Doxorubicin-induced apoptosis of human cardiac stem cells. Y-27632 also suppresses dissociation-induced apoptosis of murine prostate stem/progenitor cells. Y-27632 primes human induced pluripotent stem cells (hIPSCs) to selectively differentiate towards mesendodermal lineage via epithelial-mesenchymal transition-like modulation[1][2][3][4][5][6][7].
Applications: Cancer-Kinase/protease
Formula: C14H21N3O
Citations: ACS Appl Mater Interfaces. 2022 May 11./Acs Biomater Sci Eng. 2022 Mar 1./Acs Biomater Sci Eng. 2023 Jan 20./Acta Neuropathol Commun. 2024 Sep 14;12(1):150./Acta Pharm Sin B. 2023 May 16./Adv Healthc Mater. 2021 Feb 15;e2002103./Adv Mater Interfaces. 2024 Sep 03./Adv Sci (Weinh). 2020 Jun 17;7(15):1903583./Adv Sci (Weinh). 2023 Nov 29:e2303088./Adv Sci (Weinh). 2024 May 20:e2307216./Adv Ther. 2024 April 30./Adv Ther. 2024 Jul 18./Anal Chem. 2017 Oct 17;89(20):10841-10849./Ann Surg Oncol. 2024 Jan 4./Arch Oral Biol. 2024 Oct 21:169:106115./Bioact Mater. 14 August 2022./Bioact Mater. 2021 Jun 1./Bioact Mater. 2023 Aug./Bioact Mater. 2024 Jun 14:40:244-260./Biochem Biophys Rep. September 2022, 101299./Biochem Biophys Res Commun. 2019 Aug 20;516(2):571-577./Biochem Biophys Res Commun. 2019 Oct 29;519(1):134-140./Biochem Biophys Res Commun. 2023/Bioengineered. 2022 Apr;13(4):8747-8758./Bioengineering (Basel). 2020 Dec 18;7(4):164./Biology (Basel). 2023, 12(6), 888./Biomater Adv. 2023 Dec 26, 213751./Biomaterials. 2020 May;240:119849./Biomaterials. 2020 Nov;258:120284./Biomaterials. 2024 Jan 1:305:122462./Biomed Pharmacother. September 2022, 113465./Biomed Res Int. 2021 May 15./Biomedicines. 2024 Nov 27./bioRxiv. 2020 Aug./bioRxiv. 2020 Mar./bioRxiv. 2023 Dec 6./bioRxiv. 2023 Feb 24./bioRxiv. 2023 Jul 1./bioRxiv. 2023 Jun 22./bioRxiv. 2023 Jun 28./bioRxiv. 2023 Mar 1./bioRxiv. 2024 Aug 12:2024.08.12.607571./bioRxiv. 2024 Feb 18./bioRxiv. 2024 Nov 15:2024.11.13.623500./bioRxiv. 2024 November 15./bioRxiv. 2024 November 26./bioRxiv. 2024 September 07./bioRxiv. 2025 Feb 22:2025.02.17.638725./bioRxiv. 2025 January 15./bioRxiv. January 16, 2022./Biosci Biotechnol Biochem. 2021 Jul 23;zbab136./BMC Cancer. 2023 Jun 22;23(1):577./BMC Pulm Med. 2023 Dec 13;23(1):505./BMC Urol. 2021 Jan 6;21(1):5./Bone Res. 2022 Jan 3;10(1):1./Brain Res. 15 December 2021, 147684./Can Respir J. 10 Oct 2022./Cancer Cell Int. 2024 Jul 25;24(1):263./Cancer Cell. 2023 Jun 12;41(6):1103-1117.e12./Cancer Cell. 2024 Jun 10;42(6):1086-1105.e13./Cancer Lett. 2019 Apr 28;448:117-127./Cancer Med. 2024 Nov;13(21):e70397./Cancer Res. 2022 Dec 8;CAN-22-2370./Cancers (Basel). 2021, 13(13), 3282./Cell Biochem Biophys. 2023 Oct 6./Cell Biosci. 2024 May 22;14(1):65./Cell Death Dis. 2022 Aug 24;13(8):730./Cell Death Dis. 2023 Apr 20;14(4):280./Cell Death Dis. 2024 Aug 3;15(8):559./Cell Death Discov. 2023 Jan 25;9(1):32./Cell Discov. 2021 Apr 19;7(1):25./Cell Discov. 2022 Apr 19;8(1):35./Cell Mol Biol Lett. 2025 Jan 29;30(1):14./Cell Prolif. 2022 Aug 3;e13320./Cell Prolif. 2022 Mar 11;e13209./Cell Prolif. 2024 Jan 12:e13599./Cell Regen. 2020 Sep 3;9(1):15./Cell Rep Med. 2023 Jan 10;100911./Cell Rep Med. 2025 Feb 18;6(2):101966./Cell Rep Methods. 2024 Aug 27:100843./Cell Rep Methods. 2024 May 8:100777./Cell Rep. 2023 May 2;42(5):112445./Cell Rep. 2023 Oct 5;42(10):113213./Cell Rep. 2019 Jan 8;26(2):407-414.e5./Cell Res. 2023 Jul 17./Cell Signal. 2024 May 8:111223./Cell Stem Cell. 2020 Oct 1;27(4):646-662.e7. /Cell Stem Cell. 2022 Sep 1;29(9):1346-1365.e10./Cell Stem Cell. 2022 Sep 1;29(9):1366-1381.e9./Cell. 2024 Jul 25;187(15):3936-3952.e19./Cells. 2023 Dec 30, 13(1), 81./Cells. 2024 Aug 31./Cells. 2024 Oct 14;13(20):1697./Chem Biol Interact. 17 August 2021, 109625./Chem Eng J. 1 January 2023, 138737./Chem Eng J. 2024 Apr 1, 485, 149884./Circ Res. 2020 Oct 9;127(9):1182-1194./Clin Mol Hepatol. 2023 Feb 20./Compos B Eng. 2023 Apr 6, 110711./Connect Tissue Res. 2022 Jan 12;1-10./Curr Med Sci. 2024 Jun 27./Device. 2024 June 12/EBioMedicine. 2024 Oct 8:109:105390./EJNMMI Res. 2024 Sep 27;14(1):86./EMBO Mol Med. 2022 Dec 13;e16373./Environ Int. 2025 Jan 9./Environ Pollut. 2020 Jun;261:114153./Environ Toxicol Pharmacol. 2023 Oct 20:104301./Eur J Cell Biol. 2024 May 28;103(2):151427./Eur J Immunol. 2022 Aug;52(8):1308-1320./Exp Mol Med. 2021 Sep 21./Exp Mol Med. 2023 Jun 19./Exp Ther Med. 2021 Feb 3./Extracell Vesicle. 2025 Jun./F1000Research. 03 Aug 2022./FASEB J. 03 October 2022./FEBS J. 2024 Dec 17./Food Chem Toxicol. 2024 Oct 8:115039./Front Cell Dev Biol. 2021 Jun 24;9:670825./Front Med. 2021 Sep 23;8:746298./Front Physiol. 2020 Jun 30;11:669./Gut Microbes. 2022, 14(1): 2139978./Harvard Medical School LINCS LIBRARY/Hum Cell. 2024 Nov 4;38(1):13./Hum Mol Genet. 2022 Aug 10;ddac190./Immunity. 2022 Mar 15;S1074-7613(22)00124-8./Int Immunopharmacol. 2025 Jan 17:148:114068./Int J Biol Sci. 2022 Aug 29;18(14):5459-5474./Int J Chron Obstruct Pulmon Dis. 2024 Jul 8:19:1591-1601./Int J Mol Med. 2024 Nov;54(5):99./Int J Mol Sci. 2022, 23(23), 14637/Int J Mol Sci. 2023 Oct 31, 24(21), 15804./Int J Mol Sci. 2024 Apr 9, 25(8), 4138./Int J Stem Cells. 2023 May 30;16(2):156-167./Invest Ophthalmol Vis Sci. 2024 Oct 1;65(12):19./iScience. 19 October 2021, 103303./iScience. 2023 Aug 26./J Biol Chem. 2023 Oct 19:105361./J Biol Chem. 2025 Jan 27:108235./J Biol Eng. 2024 Jan 16;18(1):7./J Biosci Bioeng. 2020 Dec 23;S1389-1723(20)30432-1./J Bone Oncol. October 2021, 100391./J Cancer Res Clin Oncol. 2024 Sep 19;150(9):424./J Cell Mol Med. 2020 Jul;24(14):8179-8193./J Cell Mol Med. 2025 Feb;29(4):e70423./J Clin Invest. 2022 Jan 25;e154993./J Clin Med. 2019 Oct 21;8(10):1751./J Immunother Cancer. 2024 Apr 19;12(4):e008628./J Immunother Cancer. 2025 Jan 7;13(1):e009356./J Med Chem. 2019 Jul 11;62(13):6083-6101./J Neuroinflammation. 2024 Apr 10;21(1):88./J Neurosci. 2021 Jan 20;41(3):392-407./J Transl Med. 2023 Oct 10;21(1):711./J Virol. 2021 Feb 24;95(10):e02436-20./J Virol. 2023 Apr 27;e0177022./J Virol. 2025 Mar 17:e0176124./JCI Insight. 2024 Apr 23:e171916./Life Sci. 2020 Apr 1;246:117419./Life. 2021, 11(8), 789./Mat Sci Eng C-Mater. 2021, 111939./Med Sci Monit. 2018 May 27;24:3514-3523. /Methods Mol Biol. 2022 Dec 15./Methods Mol Biol. 2023;2683:53-68./Microsyst Nanoeng. 2024 Jul 15:10:97./Mol Cancer. 2024 Jan 10;23(1):12./Mol Cancer. 2024 Jun 8;23(1):125./Mol Cell. 2021 Jul 1;81(13):2736-2751.e8./Mol Med. 2023 Oct 20;29(1):139./Mol Neurobiol. 2024 Mar 20./Nat Cell Biol. 2022 Jun;24(6):858-871./Nat Commun. 2022 Apr 19;13(1):2028./Nat Commun. 2022 Jun 1;13(1):3060./Nat Commun. 2022 Sep 6;13(1):5237./Nat Commun. 2023 Apr 6;14(1):1912./Nat Commun. 2023 Aug 8;14(1):4779./Nat Commun. 2024 Aug 5;15(1):6626./Nat Commun. 2024 Feb 19;15(1):1493./Nat Commun. 2024 Feb 7;15(1):1150./Nat Commun. 2024 Mar 11;15(1):2192./Nat Commun. 2024 May 30;15(1):4590./Nat Commun. 2025 Feb 26;16(1):1999./Nat Commun. 2025 Mar 17;16(1):2635./Nat Genet. 2024 Feb;56(2):294-305./Nat Genet. 2025 Jan 14./Nat Methods. 2025 Jan 16./Nature. 2025 Feb;638(8049):225-236./Neurotherapeutics. 2021 Jan 21./NPJ Regen Med. 2022 Jun 16;7(1):31./Npj Viruses. 2024 Sep 02./Nutr Metab. 2020 Oct 26;17:91./Oncogene. 2023 Aug 31./Oncol Rep. 2020 Sep;44(3):1266-1274./Oncotarget. 2017 Jul 31;8(47):82506-82530./Patent. US20210284970A1./Patent. US20220177852A1./Patent. US20220267735A1./Patent. US20240018470A1./Patent. US20240319170A1/Patent. US20240325538A1./Patent. US20240344020A1/Patent. US20240344020A1./Patent. US20240344035A1/Patent. US20240344035A1./Pharmacol Res. 2022 Dec 16;187:106615./Phytother Res. 2024 Feb 15./Protein Cell. 2021 Feb;12(2):107-127./Reprod Toxicol. 2023 Dec 12:123:108522./Research (Wash D C). 2023 Oct 24./Research Square Preprint/Research Square Preprint. 2021 Jan./Research Square Preprint. 2021 May./Research Square Preprint. 2021 Oct./Research Square Preprint. 2022 Jan./Research Square Preprint. 2022 Jun./Research Square Preprint. 2023 May 30./Respir Res. 2022 Mar 25;23(1):70./Sci Adv. 2023 Dec 22;9(51):eadi5683./Sci Adv. 2023 Oct 27;9(43):eadg6686./Sci Rep. 2017 Dec 19;7(1):17770./Sci Rep. 2021 Dec 7;11(1):23564./Sci Rep. 2025 Mar 12;15(1):8531./Sci Rep. 2019 Dec 17;9(1):19301. /Sci Total Environ. 2020 Jul 10;725:138433./Sci Total Environ. 2022 May 18;838(Pt 2):155811./Small Methods. 2024 Oct 17:e2401144./Small. 2021 Jun 8;e2100546./Small. 2021 Nov 2;e2104773./SSRN. 2023 Feb 6./SSRN. 2024 Jan 22./STAR Protoc. 2021 Nov 5;2(4):100881./STAR Protoc. 2023 Feb 3;4(1):102092./Stem Cell Res Ther. 2024 Dec 3;15(1):463./Stem Cell Res Ther. 2024 Oct 8;15(1):350./Stem Cell Res Ther. 2019 May 31;10(1):155./Stem Cell Res. 2021, 102157./Stem Cell Res. 2021, 102217./Stem Cell Res. 2022 Sep 15;64:102916./Stem Cell Res. 2024 Feb 3:76:103327./Stem Cell Res. 2024 Mar 24, 103399./Stem Cell Res. 2025 Mar 7:85:103693./Theranostics. 2022 Mar 21;12(6):2908-2927./Theranostics. 2022 Mar 28;12(7):3131-3149./Theranostics. 2022; 12(17): 7250-7266/Theranostics. 2023 May 27;13(10):3290-3309./Toxicology. 2020 Oct;443:152573./Toxicology. 2024 Nov 9:509:153994./Transl Lung Cancer Res. 2024 Oct 31;13(10):2698-2712./Tumori. 2024 Oct 27:3008916241291301./Vaccines. 2023 May 17, 11(5), 993./Virology. 2023 May 3;583:45-51./Virology. 2024 Dec./Virulence. 2025 Dec;16(1):2466482./Am J Physiol Cell Physiol. 2023 May 1./Biochem Biophys Res Commun. 2021 Mar 18;552:142-149./Biomaterials. 2021, 120684./Biomolecules. 2023, 13(1), 69./bioRxiv. 2023 Dec 22./bioRxiv. 2023 Feb 16./bioRxiv. 2024 Dec 11:2024.12.02.626470./bioRxiv. 2024 Dec 5:2024.12.04.626665./bioRxiv. 2024 Feb 1./bioRxiv. 2024 Feb 27./bioRxiv. 2024 Jan 5./bioRxiv. 2024 November 18./bioRxiv. 2024 October 27./bioRxiv. 2024 September 14./bioRxiv. 2025 January 10./bioRxiv. April 21, 2022./Breast Cancer Res. 2021 Aug 3;23(1):82./Cancers (Basel). 2022 May 17;14(10):2463./Cancers (Basel). 2023, 15(3), 931./cell analysis. 2020 Aug./Cell Mol Gastroenterol Hepatol. 2022 Nov 24;S2352-345X(22)00238-7./Cell Rep. 2024 Jan 9;43(1):113668./Cell Rep. 2024 Mar 1;43(3):113892./Cell Rep. 2024 May 10;43(5):114206./Cell Stem Cell. 2020 Jul 2;27(1):125-136.e7. /Cell Stem Cell. 2020 Jun 4;26(6):845-861.e12. /Cell Stem Cell. 2022 Jul 7;29(7):1102-1118.e8./Cell Stem Cell. 2022 May 5;29(5):776-794.e13./Cell Stem Cell. 2022 Oct 6;29(10):1475-1490.e6./Cell Stem Cell. 2024 Jan 4;31(1):52-70.e8./Cell. 2024 Nov 14;187(23):6566-6583.e22./Curr Protoc Cell Biol. 2018 Dec;81(1):e62./Curr Protoc. 2023 Oct;3(10):e915./EMBO Mol Med. 2025 Jan 2./Environ Pollut. 2024 Mar 8:123743./Environ Sci Technol. 2024 Apr 30./Food Chem Toxicol. 2020 Jan;135:111015./Heidelberg University. 2024./Invest Ophthalmol Vis Sci. 2020 Apr 9;61(4):1. /iScience. 2022 Dec 26;26(1):105898./iScience. 2023 May 29;26(7):107001./iScience. 2024 Feb 5;27(3):109111./iScience. 2024 Jul 8;27(8):110470./J Adv Res. 2023 Oct 6:S2090-1232(23)00299-0./J Adv Res. 2024 May 8:S2090-1232(24)00184-X./J Allergy Clin Immunol. 2023 Dec 8:S0091-6749(23)02411-9./J Biol Chem. 2022 Aug 12;102374./J Biol Chem. 2024 Feb 1:105714./J Environ Sci. 2023 Feb 23./J Exp Clin Cancer Res. 2018 Jun 28;37(1):128. /J Hazard Mater. 2020 Jul 5;393:122440./J Hazard Mater. 2021 Apr 5;407:124387./J Hazard Mater. 2021 Jan 5;401:123341./J Vis Exp. 2025 Jan 31:(215)./JCI Insight. 2023 Nov 8;8(21):e167874./Life Sci. 2023 Jan 18;316:121404./Microvasc Res. 2023 Sep 28:151:104611./Mol Oncol. 2025 Mar 11./Nat Commun. 2023 Nov 27;14(1):7783./Nat Protoc. 2021 Jan;16(1):352-382./Nat Protoc. 2023 Feb 15./Nature. 2022 Jan;601(7894):600-605./Nature. 2022 Nov;611(7936):603-613./Nucleic Acids Res. 2024 Nov 21:gkae1069./Nutrients. 2023 Feb 9;15(4):887./Patent. US20180263995A1./Patent. US20220062272A1./Patent. US20250027168A1./PLoS One. 2024 Feb 7;19(2):e0295030./PLoS One. 2025 Jan 24;20(1):e0317568./Research Square Preprint. 2020 Aug 20;rs.3.rs-62758./Sci Adv. 2021 Sep 17;7(38):eabb5933./Sci Total Environ. 2023 Dec 30:913:169702./Science. 2020 Dec 4;370(6521):eaay2002./STAR Protoc. 16 December 2022, 101786./STAR Protoc. 2022 Sep 26;3(4):101720./STAR Protoc. 2023 Jul 9;4(3):102431./STAR Protoc. 2023 Nov 16;4(4):102683./STAR Protoc. 2024 Nov 27;5(4):103466./Stem Cell Res. 2024 Sep 14:81:103562./Stem Cell Res. October 2021, 102544./Biomedicines. 2022 Apr 18;10(4):928. /Dev Cell. 2025 Feb 7:S1534-5807(25)00034-6.
References: [1]Ishizaki T, et al. Pharmacological properties of Y-27632, a specific inhibitor of rho-associated kinases. Mol Pharmacol. 2000 May;57(5):976-83./[2]Xue ZW, et al. Rho-associated coiled kinase inhibitor Y-27632 promotes neuronal-like differentiation of adult human adipose tissue-derived stem cells.Chin Med J (Engl). 2012 Sep;125(18):3332-5./[3]Inan S, et al. Antiepileptic effects of two Rho-kinase inhibitors, Y-27632 and fasudil, in mice. Br J Pharmacol. 2008 Sep;155(1):44-51./[4]Tada S, et al. A selective ROCK inhibitor, Y27632, prevents dimethylnitrosamine-induced hepatic fibrosis in rats. J Hepatol. 2001 Apr;34(4):529-36./[5]Maldonado M, et al. ROCK inhibitor primes human induced pluripotent stem cells to selectively differentiate towardsmesendodermal lineage via epithelial-mesenchymal transition-like modulation. Stem Cell Res. 2016 Sep;17(2):222-227./[6]Kan L, et al. Rho-Associated Kinase Inhibitor (Y-27632) Attenuates Doxorubicin-Induced Apoptosis of Human Cardiac Stem Cells. PLoS One. 2015;10(12):e0144513. Published 2015 Dec 8./[7]Zhang L, et al. ROCK inhibitor Y-27632 suppresses dissociation-induced apoptosis of murine prostate stem/progenitor cells and increases their cloning efficiency. PLoS One. 2011;6(3):e18271. Published 2011 Mar 28./[8]Svoboda KK, et al. ROCK inhibitor (Y27632) increases apoptosis and disrupts the actin cortical mat in embryonic avian corneal epithelium. Dev Dyn. 2004;229(3):579-590.
CAS Number: 146986-50-7
Molecular Weight: 247.342
Compound Purity: 99.91
Research Area: Cancer
Solubility: DMSO : 25 mg/mL (ultrasonic;warming;heat to 60°C)/H2O : 1 mg/mL (ultrasonic;warming;heat to 60°C)
Target: Apoptosis;Organoid;ROCK
Deutsch
English
